Brigimadlin

Summary

Brigimadlin (CHEMBL5314455) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including dedifferentiated liposarcoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 10
• Chemistry: 591.5 Da · C31H25Cl2FN4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314455
Name	Brigimadlin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	129264140
Molecular formula	C31H25Cl2FN4O3
Molecular weight	591.5
InChIKey	AMTXDBGKYPDTTA-SJVQGLCSSA-N

SMILES: CC1=C(C=CC2=C3C[C@H]4[C@@H](N3N=C12)[C@@H]([C@]5(N4CC6CC6)C7=C(C=C(C=C7)Cl)NC5=O)C8=C(C(=CC=C8)Cl)F)C(=O)O

IUPAC name: (3S,10’S,11’S,14’S)-6-chloro-11’-(3-chloro-2-fluorophenyl)-13’-(cyclopropylmethyl)-6’-methyl-2-oxospiro[1H-indole-3,12’-8,9,13-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-1,3,5,7-tetraene]-5’-carboxylic acid

Also known as: BI 907828, BI-907828, BI907828, Brigimadlin, Brigimadlina, Brigimadline, Brigmadlin, BRIGIMADLIN

Patent coverage: 4 distinct patent families (10 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: E3 ubiquitin-protein ligase Mdm2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MDM2	8.7	IC50	2	nM	CHEMBL_ACT_25878557
MDM2	8.7	IC50	2	nM	CHEMBL_ACT_28049540

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dedifferentiated liposarcoma	3	MONDO:0020563	EFO:0003085
neoplasm	1	MONDO:0005070	EFO:0000616
glioblastoma	1	MONDO:0018177	EFO:0000519

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	3
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05218499	PHASE2/PHASE3	COMPLETED	Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793	PHASE3	COMPLETED	Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06370871	PHASE3	WITHDRAWN	Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
NCT06619509	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT05512377	PHASE2	TERMINATED	Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT06084689	PHASE2	WITHDRAWN	Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
NCT03449381	PHASE1	COMPLETED	This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
NCT03964233	PHASE1	COMPLETED	A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
NCT05372367	PHASE1	COMPLETED	A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
NCT05613036	PHASE1	COMPLETED	A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).